Le Lézard
Classified in: Health, Science and technology
Subject: TRI

Lactic Acid Bacteria in Kimchi Reduce Cholesterol in Blood


SEOUL, South Korea, Nov. 26, 2018 /PRNewswire/ -- World Institute of Kimchi, which discovers and promotes kimchi's scientific excellence announces that the results of an animal test showed that lactic acid bacteria isolated from kimchi (a probiotic) significantly reduced cholesterol levels in blood.

Prof. Young-Jun Kim's research team, at the Department of Food and Biotechnology at Korea University, which is one of the research teams in World Institute of Kimchi in Korea, studied three mouse groups fed with a high-cholesterol diet (one group was fed saline; the second group had a daily intake of 0.1 billion cells of Lactobacillus plantarum LRCC 5273 isolated from kimchi; and the third group had a daily intake of 0.1 billion cells of Lactobacillus plantarum LRCC 5279 isolated from kimchi). They compared the blood cholesterol levels of these 3 groups and 1 control group fed with normal feed after 6 weeks. The results showed that the total cholesterol and LDL cholesterol in the blood were reduced, and the cholesterol in feces was increased in mice that were fed with a diet containing LRCC 5273. The increased levels of fecal cholesterol indicated that a greater amount of cholesterol was discharged. This finding (Lactobacillus plantarum LRCC 5273 isolated from Kimchi ameliorates diet-induced hypercholesterolemia in C57BL/6 mice) was published in a recent issue of the international journal "Bioscience, Biotechnology, and Biochemistry".

The research team explained that Lactobacillus plantarum LRCC 5273 isolated from kimchi increased the release of cholesterol in feces and stimulated the excretion of bile acid in the small intestine. This was thought to reduce blood cholesterol, ultimately improving the health of blood vessels.

Among the lactic acid bacteria isolated from kimchi, the effect of blood cholesterol reduction varied depending on the bacterial species. The blood cholesterol reduction effect of LRCC 5273 was higher than that of LRCC 5279.

Dr. Jaeho Ha, a general director of World Institute of Kimchi, explained, "Kimchi reduces the amount of blood cholesterol and decomposes blood clots that form as a result of blood coagulation." He added, "The cholesterol reduction effect is much higher in aged kimchi than in freshly made kimchi."

About World Institute of Kimchi

A government-funded research institute established to perform research and development related to kimchi, to lead national technological innovation, nature and develop the kimchi industry that will boost the national growth. It performs overall research and development related to kimchi, in order to lead national technological innovation and nurture and develop the kimchi industry that will boost the national growth.

SOURCE World Institute of Kimchi


These press releases may also interest you

at 01:05
Elliptic Labs (OSE: ELABS), a global AI software company and the world leader in AI Virtual Smart Sensorstm currently deployed in over 500 million devices, is shipping its AI Virtual Proximity Sensortm INNER BEAUTY® on vivo's newly announced iQOO Z9...

at 00:50
OKX, a leading Web3 technology company, has issued updates for April 25, 2024. OKX Wallet Now Integrated with XION, a User-First ...

at 00:30
Wego, the largest online travel marketplace in the Middle East and North Africa (MENA), is thrilled to announce its continued partnership with the Tourism Authority of Thailand (TAT) for the fourth consecutive year, showcasing the unparalleled beauty...

at 00:30
ENOC Group, a leading integrated global energy player, has appointed the innovative technology loyalty partner, Loyyal, to integrate Access Point, their self-service platform, into the Group's rewards programme. This move will revolutionize the 'YES'...

at 00:05
Systal Technology Solutions, a global managed network, cloud, and security transformation specialist, today announces the opening of its new Network Operations Center (NOC) in Tampa, Florida. This marks the latest milestone in Systal's recent growth...

at 00:05
ImmunityBio, Inc. , an immunotherapy company, today announced positive overall survival results in the QUILT 3.055 study of 2nd- and 3rd-line NSCLC patients who progressed after checkpoint inhibitor therapy (pembrolizumab, nivolumab, or atezolizumab)...



News published on and distributed by: